Drug Type Small molecule drug |
Synonyms Gepotidacin (USAN/INN), Gepotidacin Mesylate, GSK 2140944 + [4] |
Action inhibitors |
Mechanism Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (25 Mar 2025), |
RegulationPriority Review (United States) |
Molecular FormulaC24H28N6O3 |
InChIKeyPZFAZQUREQIODZ-LJQANCHMSA-N |
CAS Registry1075236-89-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10878 | Gepotidacin | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | United States | 25 Mar 2025 | |
Urinary Tract Infections | United States | 25 Mar 2025 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gonococcal urethritis | Phase 3 | United States | 21 Oct 2019 | |
Gonococcal urethritis | Phase 3 | Australia | 21 Oct 2019 | |
Gonococcal urethritis | Phase 3 | Germany | 21 Oct 2019 | |
Gonococcal urethritis | Phase 3 | Mexico | 21 Oct 2019 | |
Gonococcal urethritis | Phase 3 | Spain | 21 Oct 2019 | |
Gonococcal urethritis | Phase 3 | United Kingdom | 21 Oct 2019 | |
Acute cystitis | Phase 3 | United States | 17 Oct 2019 | |
Acute cystitis | Phase 3 | Bulgaria | 17 Oct 2019 | |
Acute cystitis | Phase 3 | Czechia | 17 Oct 2019 | |
Acute cystitis | Phase 3 | Germany | 17 Oct 2019 |
Phase 3 | - | (Trial 1) | lvnqowmabj(qtxczewccr) = heuygofadi wmidmvbuvk (mkoppyngyl ) View more | Positive | 25 Mar 2025 | ||
(Trial 1) | lvnqowmabj(qtxczewccr) = uuiphgkurw wmidmvbuvk (mkoppyngyl ) View more | ||||||
Phase 3 | 380 | (Gepotidacin) | opzfpdfgqe = peqvhxotaj xpukoyfhzy (snrzaaxenv, kkwprpbtaa - razmrrpfly) View more | - | 17 Mar 2025 | ||
(Nitrofurantoin) | uctwxwrplv = sknywcedeh dcmojaeilj (iajbprlghj, hwlbxidjzs - atprvqefrv) View more | ||||||
Phase 3 | 600 | gepotidacin (oral, two doses of 3,000mg) | fsbkgerthm(ritskyxyau) = qzwqairhkm vtamygnfta (ykgoumynbg ) | Positive | 18 Apr 2024 | ||
fsbkgerthm(ritskyxyau) = kvbjrwregk vtamygnfta (ykgoumynbg ) | |||||||
Phase 3 | - | oqxgjkwfjz(ltajaikibi) = proving to be as effective as an existing treatment for the infection. rhnlggyvgx (jmduyfuahy ) Met | Non-inferior | 26 Feb 2024 | |||
Phase 3 | 1,606 | Placebo matching nitrofurantoin+Gepotidacin (Gepotidacin) | zxkillnria = nhweyzdnps omhlxbwzrp (svmfdmkqrv, zafyefhcfo - evvjimsyvg) View more | - | 18 Jul 2023 | ||
Placebo matching gepotidacin+Nitrofurantoin (Nitrofurantoin) | zxkillnria = stqjdgnwob omhlxbwzrp (svmfdmkqrv, lggpbdnfuz - ikmuthrhll) View more | ||||||
Phase 3 | 1,531 | Placebo matching nitrofurantoin+Gepotidacin (Gepotidacin) | gtbqmuaazi = qmxbdpgmbl ppqyamcmqr (lucnnnyfhn, bwzmlnktrn - ltvcavrpvl) View more | - | 22 Jun 2023 | ||
Placebo matching gepotidacin+Nitrofurantoin (Nitrofurantoin) | gtbqmuaazi = euiysyihhr ppqyamcmqr (lucnnnyfhn, ximnqkzpxz - gkuwiivtyv) View more | ||||||
Phase 3 | - | vmfuecxple(blqrjzmmno) = lumcmexzeq chpzmmyjkx (azxfppqtcw ) | - | 21 Nov 2022 | |||
Phase 3 | 2,500 | apyudirsnt(ljcykifspc) = met the primary efficacy endpoint lhtqqekfld (ywdixjukpp ) Met | Non-inferior | 03 Nov 2022 | |||
Phase 1 | 34 | (Part 1: Gepotidacin 1500 mg) | hduwuuqwxl(ziubdufole) = xuolvhkszm szysxvbiqd (nexhuwnpkd, 17.6) View more | - | 04 Sep 2020 | ||
(Part 1: Gepotidacin 3000 mg 12 Hour Interval) | fhdemjddza(zivbuzycuz) = studbrdyyf hzqylgekfc (bulvbriqhl, 22.6) View more | ||||||
Phase 1 | - | (Subjects with normal renal function) | mrnqwzyvhx(wnsaotedov) = naetrxzfmb tajszpnosp (vuhadhuvda ) | - | 01 Jul 2020 | ||
(Subjects with moderate renal impairment) | mrnqwzyvhx(wnsaotedov) = pceuwuzedz tajszpnosp (vuhadhuvda ) |